$2.0501
0.0101[0.50%]
At close: May 9
$2.0501
0[0.00%]
PreMarket: 8:47AM EDT
Esperion Therapeutics
(NASDAQ:ESPR)Latest News for Esperion Therapeutics Stock (NASDAQ:ESPR)
Esperion Therapeutics Stock (NASDAQ: ESPR)
Categories: All
Wednesday, May 08, 2024
Tuesday, May 07, 2024
- Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price TargetBenzinga Newsdesk - 1 day ago
- Esperion Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.Benzinga Newsdesk - 1 day ago
- Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock SoarsVandana Singh - 1 day ago
- CORRECTION: Esperion Therapeutics Sees FY24 Operating Expenses $225M-$245M, Including $20M In Non-cash Expenses Related To Stock CompensationBenzinga Newsdesk - 1 day ago
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - 2 days ago
- Esperion Therapeutics Q1 EPS $0.34 Beats $0.05 Estimate, Sales $137.74M Beat $84.51M EstimateBenzinga Newsdesk - 2 days ago
Friday, April 12, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Monday, April 08, 2024
- Esperion Therapeutics shares are trading lower. The company announced the presentation of new data from CLEAR Outcomes.Benzinga Newsdesk - Apr 8, 2024, 2:20PM
- Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Apr 8, 2024, 5:15AM
- Reported Sunday, Esperion Presents New Data From CLEAR Outcomes At ACC.24 Highlighting Value Of NEXLETOL® Tablets In Diverse PopulationsBenzinga Newsdesk - Apr 8, 2024, 2:41AM
Wednesday, April 03, 2024
Monday, March 25, 2024
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre To Be Presented At ACC.24Benzinga Newsdesk - Mar 25, 2024, 4:01PM
- Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Mar 25, 2024, 2:44PM
- HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price TargetBenzinga Newsdesk - Mar 25, 2024, 1:01PM
- Why Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?Vandana Singh - Mar 25, 2024, 9:24AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Mar 25, 2024, 9:05AM
- Market-Moving News for March 25thBenzinga Newsdesk - Mar 25, 2024, 8:40AM
- Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 25, 2024, 8:03AM
- Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price TargetBenzinga Newsdesk - Mar 25, 2024, 7:35AM
- Esperion shares are trading higher after the FDA approved broad labels for NEXLETOL and NEXLIZET to prevent heart attacks and cardiovascular procedures, regardless of statin use.Benzinga Newsdesk - Mar 25, 2024, 6:44AM
- Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market SessionAvi Kapoor - Mar 25, 2024, 5:34AM
Friday, March 22, 2024
- Esperion Therapeutics Inc Says European Cardiovascular Risk Reduction Label Determination Anticipated In Q2 2024Benzinga Newsdesk - Mar 22, 2024, 3:13PM
- U.S. FDA Approves Broad New Labels For NEXLETOL And NEXLIZET To Prevent Heart Attacks And Cardiovascular Procedures In Both Primary And Secondary Prevention Patients, Regardless Of Statin UseBenzinga Newsdesk - Mar 22, 2024, 3:12PM
- Daiichi Sankyo Europe GmbH And and Esperion Therapeutics Announce CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsBenzinga Newsdesk - Mar 22, 2024, 11:06AM
Wednesday, February 28, 2024
Tuesday, February 27, 2024
- Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price TargetBenzinga Newsdesk - Feb 27, 2024, 2:47PM
- Esperion Therapeutics Expects FY24 Operating Expenses Of $225M-$245M, Including $20M In Non-cash Expenses Related To Stock CompensationBenzinga Newsdesk - Feb 27, 2024, 6:10AM
- Esperion Therapeutics Q4 Retail Prescription Equivalents Grew 44% YoY, Projects Momentum Within Segment Into 1H 2024Benzinga Newsdesk - Feb 27, 2024, 6:06AM
- Esperion Therapeutics Q4 EPS $(0.50) Misses $(0.48) Estimate, Sales $32.25M Beat $28.70M EstimateBenzinga Newsdesk - Feb 27, 2024, 6:03AM
- Earnings Scheduled For February 27, 2024Benzinga Insights - Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Tuesday, January 30, 2024
Friday, January 19, 2024
- Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Jan 19, 2024, 1:05PM
- Why Super Micro Computer Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Jan 19, 2024, 8:13AM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Jan 19, 2024, 8:06AM
- Esperion Prices $85.1M Public Offering Of 56.7M Common Share At $1.50/ShareBenzinga Newsdesk - Jan 19, 2024, 2:16AM
Thursday, January 18, 2024
Wednesday, January 17, 2024
Friday, January 12, 2024
Wednesday, January 03, 2024
- Nasdaq Down Over 100 Points; Sidus Space Shares Spike HigherAvi Kapoor - Jan 3, 2024, 2:20PM
- Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Jan 3, 2024, 12:58PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Jan 3, 2024, 12:31PM
- Crude Oil Gains Over 3%; US Manufacturing Activity Contracts For 14th Consecutive MonthAvi Kapoor - Jan 3, 2024, 12:01PM
- Esperion Therapeutics shares are trading lower after the company and Daiichi Sankyo Europe announced a $125 million amendment to their collaboration that included a resolution to its pending litigation.Benzinga Newsdesk - Jan 3, 2024, 10:54AM